Publications by authors named "Perez-Martinez O"
Introduction: Our aim was to estimate the risk of pneumonia, admission to intensive care unit (ICU) or death in individuals ≥65 years old admitted to hospital with RSV, compared to influenza or COVID-19.
Methods: We included hospitalised patients from Severe Acute Respiratory Infection Surveillance in Spain between 2021-2024, aged ≥65 years, laboratory confirmed for RSV, influenza or SARS-CoV-2. Using a binomial regression with logarithmic link, we estimated the relative risk (RR) of pneumonia, ICU admission and in-hospital mortality, in patients with RSV compared to influenza or SARS-CoV-2, adjusting for age, sex, season and comorbidities.
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol.
Hum Vaccin Immunother
December 2024
Article Synopsis
- Nirsevimab has been approved for universal RSV prevention in infants, with a study (NIRSE-GAL) launched in Galicia in September 2023 to assess its effectiveness against various RSV-related health issues.
- The study will monitor infants during the RSV season, focusing on different groups including newborns and those at high risk, and will track outcomes until significant events occur or the study concludes.
- Data analysis will utilize sophisticated models and will include safety monitoring of nirsevimab, with results communicated through scientific publications and conferences.
Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.
Influenza Other Respir Viruses
May 2024
Article Synopsis
- The study analyzed data from Spain's surveillance system for severe acute respiratory infections to assess the effect of nirsevimab on infants born from April 1, 2023, onward.
- Researchers compared actual RSV hospitalizations in children under one year old from late 2023 to early 2024 with expected numbers based on previous seasons.
- The results showed a significant reduction in hospitalizations, estimating between 9,364 to 9,875 fewer cases, which represents a 74% to 75% decrease in RSV-related hospitalizations.
Article Synopsis
- Galicia, Spain, launched a program in September 2023 to give nirsevimab for RSV prevention in infants, focusing on newborns, those under 6 months, and high-risk children aged 6-24 months.
- The interim analysis of the study, using data from Sept 25 to Dec 31, 2023, assesses nirsevimab's effectiveness in preventing different levels of RSV-related hospitalizations and complications.
- The study compares the results with data from previous RSV seasons to calculate how many cases of hospitalization were potentially avoided due to the immunization campaign.
Article Synopsis
- The study investigates the impact of respiratory syncytial virus (RSV) on infants, highlighting that the effects go beyond just hospitalization and require better understanding for future healthcare planning.
- Researchers analyzed data from 6626 children, comparing those hospitalized with severe RSV to those who weren't, focusing on healthcare visits and prescriptions related to respiratory issues.
- Results showed that severe RSV significantly increased visits to primary healthcare for conditions like wheezing and lower respiratory infections, indicating a substantial burden even after initial hospitalization.
Background: With more than 7500 cases reported since April 2022, Spain has experienced the highest incidence of mpox in Europe. From 12 July onward, the modified vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure prophylaxis for those receiving pre-exposure prophylaxis for human immunodeficiency virus (HIV-PrEP). Our aim was to assess the effectiveness of 1 dose of MVA-BN vaccine as pre-exposure prophylaxis against mpox virus (MPXV) infection in persons on HIV-PrEP.
View Article and Find Full Text PDFObjective: Since the beginning of the pandemic, it has become necessary to know the epidemiological evolution of SARS-CoV-2. Therefore, this study aims to describe the characteristics of the casuistry of COVID-19 in health and social-health workers in the health area of A Coruña and Cee during the first epidemic wave, as well as to determine the association between the clinical profile and/or its duration and the condition of RT-PCR repositivization.
Materials And Methods: During the study period, 210 cases belonging to healthcare and social-healthcare workers from the healthcare area of A Coruña and Cee were diagnosed.
Objectives: To know the impact of COVID-19 in incidence and lethality in nursing homes in Galicia.
Methods: This is a descriptive study of nursing homes residents and workers with confirmed COVID-19. The analysis spanned from March 1, 2020 to March 27, 2022, stratified into 6 periods (one per wave).
Description and Survival of Stage I and II Lung Cancer Patients.
Arch Bronconeumol (Engl Ed)
August 2018
Introduction: The objective of our study was to describe the characteristics of patients diagnosed with stage I and II lung cancer in the health area of A Coruña (Galicia) and to determine their overall survival according to certain variables.
Methods: Retrospective case series in patients diagnosed between January 2011 and December 2015 with stage I and II primary lung cancer with a minimum follow-up of 18 months.
Results: 158 patients were included, 99 at stage I, with a median age of 69 years [range 20-90], predominantly men (81%).